Skip to content
Biodatica
Start free

Gruppo Oncologico del Nord-Ovest

Aviano, Italy

OncologyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

May 2025Trial registeredMay 25, 2025Source filing (opens the source filing in a new tab)

Momentum

51no change

Momentum 51 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Mar 27, 2025

    Pancreatic Adenocarcinoma Advanced or Metastatic · RECRUITING · sponsor: Gruppo Oncologico del Nord-Ovest · Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

    ClinicalTrials.gov · NCT06897644 (opens the source filing in a new tab)

  2. Trial

    PHASE2/PHASE3 registered

    Nov 7, 2023

    Biliary Tract Cancer, Cholangiocarcinoma · RECRUITING · sponsor: Gruppo Oncologico del Nord-Ovest · CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

    ClinicalTrials.gov · NCT06037980 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources